For the first time in Piramal Pharma Solutions’ history, the CDMO’s revenue earned on innovation programs has surpassed that of generic projects. Over the past five years, innovation revenue has grown from 35% of total revenues to more than 50%, representing a CAGR of 20%. The 50% figure represents work performed for pharma innovator customers across discovery, development and on-patent commercial manufacturing. It includes projects spanning preclinical development through Phases I, II, and ...